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Recent studies point to a pivotal role of Polycomb
repressive complex 2 (PRC2) in stem cell function
and cancer. Loss-of-function approaches targeting
individual PRC2 subunits have, however, generated
findings that are difficult to reconcile. Here, we pre-
vent assembly of both Ezh1- and Ezh2-containing
PRC2 complexes by conditional deletion of Eed, a
core subunit, and assess hematopoiesis. We find
that deletion of Eed exhausts adult bone marrow
hematopoietic stem cells (HSCs), although fetal liver
HSCs are produced in normal numbers. Eed-null
neonatal HSCs express HSC signature genes but
are defective in maintenance and differentiation.
Comparative gene expression profiling revealed
that neonatal and adult HSCs lacking Eed upregu-
lated gene sets of conflicting pathways. Deletion of
Cdkn2a, a PRC2 target gene, in Eed-null mice en-
hances hematopoietic stem/progenitor cell (HSPC)
survival but fails to restore HSC functions. Taken
together, our findings define developmental-stage-
specific requirements for canonical PRC2 complexes
in normal HSC function.
INTRODUCTION
Gene expression and cell fate are controlled by transcription
factors acting in concert with epigenetic regulators. Perturbation
of epigenetic pathways is associated with altered stem cell func-
tion and oncogenesis (Margueron and Reinberg, 2011; Sauva-
geau and Sauvageau, 2010). Polycomb group proteins represent
a major class of epigenetic regulators in diverse developmental
contexts and participate in transcriptional repression. Polycomb
repressive complex 2 (PRC2) consists of three core subunits:
Eed (embryonic ectoderm development), Suz12 (suppressor of
zeste 12 homolog), and Ezh2 (enhancer of zeste homolog 2),
which possesses histone methyltransferase activity (Kuzmichev
et al., 2002; Margueron and Reinberg, 2011). PRC2 is required
for proper differentiation of embryonic stem cells (ESCs) and
somatic stem cells, such as skin stem cells (Ezhkova et al.,68 Cell Stem Cell 14, 68–80, January 2, 2014 ª2014 Elsevier Inc.2009, 2011; Shen et al., 2008). The existence of Ezh1, a homolog
of Ezh2, confounds simple interpretation of Ezh2 knockout ex-
periments as Ezh1 associates with Eed and Suz12 to form an
alternative PRC2 complex that partially compensates for the
loss of Ezh2 in some cell contexts (Ezhkova et al., 2011;
Margueron et al., 2008; Shen et al., 2008). Ezh2 expression
generally correlates with cell proliferation, whereas Ezh1 expres-
sion is higher in nonproliferative adult tissues (Margueron et al.,
2008). Although PRC2 was originally identified as a dedicated
suppressor associated with the presence of the H3K27me3
mark at target genes, increasing evidence suggests that individ-
ual componentsmay occupy active genes, a setting in which his-
tone methyltransferase activity may or may not be required (Lee
et al., 2011; Mousavi et al., 2012; Xu et al., 2012).
Differentiation and self-renewal of hematopoietic stem cells
(HSCs) are tightly regulated to generate sufficient mature cells
to replace aged cells and maintain the stem cell pool. In mouse
and human, fetal liver (FL) and bone marrow (BM) are two major
sites of HSC residence (Orkin and Zon, 2008). FL and neonatal
BM HSCs actively self-renew to expand the HSC pool in the
growing animal (Bowie et al., 2006; Harrison et al., 1997). In
contrast, adult BM HSCs are mostly quiescent under steady-
state conditions (Bowie et al., 2006; Cheng et al., 2000; Essers
et al., 2009).
The requirements for PRC2 in hematopoiesis are inadequately
defined and remain controversial. N-ethyl-N-nitrosourea (ENU)-
induced mutations in mice have suggested that Eed and Suz12
restrict proliferation of HSCs. Paradoxically, overexpression of
Ezh2 enhances HSC self-renewal (Herrera-Merchan et al.,
2012; Kamminga et al., 2006). Similar approaches have sug-
gested that Polycomb repressive complex-1 (PRC1 [Bmi-1
PRC1]) is antagonistic to PRC2 in HSC proliferation (Majewski
et al., 2010). The roles of PRC2 in hematopoiesis are of particular
interest given the recent discoveries of loss-of-function and
altered-specificity EZH2 mutants, as well as mutations in EED,
SUZ12, and JARID2, in various hematopoietic malignancies
(Lohr et al., 2012; McCabe et al., 2012; Morin et al., 2010; Niko-
loski et al., 2010; Ntziachristos et al., 2012; Puda et al., 2012;
Simon et al., 2012; Ueda et al., 2012; Zhang et al., 2012). Over-
expression of PRC2 subunits, particularly EZH2, has also been
linked to various cancers (Simon and Lange, 2008; Varambally
et al., 2002).
Although several mouse models have been generated and
utilized to study the role of PRC2 in hematopoiesis, its role
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Figure 1. Loss of Ezh2 Does Not Signifi-
cantly Affect the Frequencies and Numbers
of LT- HSCs in FL and Neonatal BM
(A) Sample plots of FACS analysis for FL LT-HSCs.
(B and C) Comparison of frequencies and total cell
numbers of LT-HSCs from E14.5 (B) and E17.5 (C)
FLs between Ezh2Fl/Fl (Ezh2Fl/FlVavWT) and Ezh2D/D
(Ezh2KO) embryos. Data are shown as mean ± SD.
(D)SampleplotsofFACSanalysis forBMLT-HSCs.
(E and F) Comparison of BM LT-HSC frequencies
and total cell numbers for 9-day-old (E) and 15-
day-old (F) Ezh2Fl/Fl and Ezh2KO neonates. Data
are shown as mean ± SD.
(G–I) Quantitative RT-PCR analysis of Ezh1, Ezh2,
and Eed mRNAs in LT-HSCs from E14.5 FLs and
from different age mouse BM. After normalized
with expression value of glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), expression
values of indicated genes in samples presented in
each plot are compared to the smallest number
within the group, which is set to 1. Data are shown
as mean ± SD.
Cell Stem Cell
PRC2 Regulates HSC Differentiation and Maintenanceremains elusive due to issues such as redundancy of Ezh
homologs and difficulties in distinguishing effects of canonical
versus noncanonical PRC2 functions, which are mediated by
Ezh1/Ezh2 or Suz12 independent of H3K27me3 (Lee et al.,
2011; Mousavi et al., 2012; Su et al., 2005; Xu et al., 2012).
Initially, we observed that loss of Ezh2 alone results in limited
effects on the maintenance of long-term HSCs (LT-HSCs),
possibly due to in vivo compensation by Ezh1. To address
the role of canonical PRC2 in hematopoiesis, while leavingCell Stem Cell 14, 68–8its possible noncanonical functions
minimally affected, we generated a con-
ditional knockout allele of Eed in the
mouse. This strategy circumvents the
need to infer possible redundancy of
Ezh1 in the setting of Ezh2 loss. Using
this approach, we have defined complex
and essential roles of canonical PRC2
functions in HSCs.
RESULTS
Ezh2 Is Dispensable for
Maintenance of LT-HSCs
We first explored the requirement of Ezh2
for maintenance of both FL and BM LT-
HSCs by utilizing Ezh2Fl/FlVavCre mice
(referred to as Ezh2KO). VavCre is specif-
ically expressed in hematopoietic cells,
including HSCs (Stadtfeld and Graf,
2005). Ezh2KO embryos appeared mor-
phologically normal, and there were no
significant differences in the frequencies
and total numbers of FL LT-HSCs
(LinCD48CD150+Mac1+Sca-1+ cells)
between Ezh2Fl/Fl and Ezh2KO embryos
at embryonic day 14.5 (E14.5) and E17.5(Figures 1A–1C). Similarly, the frequencies and total numbers
of BM LT-HSCs (LinSca-1+Kit+CD48CD150+) were com-
parable between Ezh2Fl/Fl and Ezh2KO animals at 9 days and
15 days old, respectively (Figures 1D–1F). Moreover, inducible
deletion of Ezh2 by Mx1Cre (Ku¨hn et al., 1995) in adult HSCs
did not impair HSC functions in a transplantation setting
(data not shown). Taken together, these data indicate that
Ezh2 is dispensable for the maintenance of both FL and BM
LT-HSCs.0, January 2, 2014 ª2014 Elsevier Inc. 69
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Figure 2. Eed Deletion Causes Pancyto-
penia in Neonates without Affecting FL
LT-HSCs
(A) Schematic diagram of the Eed locus, the
targeting vector, and the knockout allele. Light
blue boxes depict exons of Eed; heavier lines
represent introns of Eed gene and other genomic
sequences.
(B) Southern blot validation of gene targeting.
(C) PCR validation of neomycin cassette excision.
(D) Western blot validation of a complete loss
of H3K27 methylation in Eed/ ESCs compared
to EedFl/Fl and Ezh2/ ESCs.
(E) Comparison of frequencies (left) and total
numbers per FL (right) of LT-HSCs between
EedFl/FL (EedFl/FlVavWT) and EedD/D (EedKO) E17.5
FLs. Data are shown as mean ± SD.
(F) Representative photos of bones and spleens of
9-day-old WT and EedKO mice.
(G) Total white and red blood cell counts of 9-day-
old WT (n = 4) and EedKO (n = 5) mice. Data are
shown as mean ± SD.
See also Figure S1.
Cell Stem Cell
PRC2 Regulates HSC Differentiation and MaintenanceEed Is Dispensable for the Development of FL HSCs
Because Ezh1 and Ezh2 partially overlap in their functions in
ESCs and skin stem cells (Ezhkova et al., 2009, 2011; Shen
et al., 2008), we reasoned that Ezh1 might compensate for
Ezh2 loss in HSCs. To test this, we first determined the expres-
sion of Ezh1, Ezh2, and Eed in LT-HSCs from E14.5 FL andBMat
different ages. Ezh2 mRNA was 1.5-fold lower in neonatal BM
compared to FL LT-HSCs and was further decreased in the adult
(Figure 1G). In contrast, Ezh1 mRNA was upregulated 5.4-fold
from fetal to neonatal stage and progressively increased with
age (Figure 1H). Eed mRNA was modestly upregulated in
LT-HSCs from the fetal to neonatal stage (1.8-fold) but
remained largely constant thereafter (Figure 1I). These results
suggest that the abundance of the PRC2 complex may be lower
in FL HSCs than in postnatal BM HSCs and that the ratio of
Ezh1- versus Ezh2-PRC2 is higher in postnatal BM HSCs than
in FL HSCs.
To assess directly the role of PRC2 during hematopoiesis,
we generated Eed conditional knockout mice (Figures 2A–
2C). To validate the consequences of Eed loss, which is
predicted to prevent the assembly of both Ezh1- and Ezh2-
PRC2, we examined the levels of histone methylation in Eed/
ESCs. In contrast to Ezh2/ ESCs, which retained substantial70 Cell Stem Cell 14, 68–80, January 2, 2014 ª2014 Elsevier Inc.H3K27me1, Eed/ ESCs lacked both
H3K27me1 and H3K27me3 (Figure 2D).
Deletion of Eed did not alter the
methylation levels at other H3 lysine
residues (Figure 2D; data not shown).
These results demonstrate that Eed is
an essential core subunit of PRC2 and
loss of Eed ablates canonical PRC2
function.
To study the role of Eed in HSCmainte-
nance and function, we generated
EedFl/FlVavCre (referred to as EedKO) ani-
mals. EedKO embryos developed nor-mally (Figure S1A available online). No significant differences in
FL LT-HSC frequencies (0.012% ± 0.001% versus 0.009% ±
0.002%; p = 0.12) or cell numbers (7,664 ± 1,259 HSCs/FL
versus 6,323 ± 1,640HSCs/FL; p = 0.28) were observed between
E17.5 EedKO and control embryos, respectively (Figure 2E). Of
note, EedKO embryos had a 3-fold reduction in B-lineage cells,
suggesting a requirement of Eed for normal B-lineage cell
development (Figure S1B).
EedMutant Neonates Develop Pancytopenia
EedKO pups were born at a normal Mendelian ratio and were
indistinguishable from wild-type (WT) littermates at birth (data
not shown). However, during the immediate postnatal period,
mutants became pale and runted and eventually succumbed
to bacterial infection within 5–12 days after birth (Figure 6A;
data not shown). Notably, bones from EedKO neonates were
pale and hypocellular and spleens were also pale and underde-
veloped (Figures 2F and 3C). Complete blood counts revealed
profound leukopenia and anemia in EedKO neonates (Figure 2G).
Few myeloid or B-lineage cells were present in the EedKO BM,
spleen, or blood (Figure S1C; data not shown). These findings
demonstrate that Eed is essential for normal hematopoiesis in
postnatal animals.
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Figure 3. EedKO BM HSCs Are Defective in Differentiation
(A and B) Sample FACS plots (A) showing 9-day-old WT (n = 5), Ezh2KO (n = 5), and EedKO (n = 4) BM LSK and myeloid progenitor cells (MyePro; LinSca-1Kit+).
The percentage of each population is plotted in graph (B). Data are presented as mean ± SD.
(C) Comparison of LT-HSC frequencies (as percentage of total BM cells, left), total live BM cells per mouse (middle), and total BM LT-HSCs per mouse (right)
between WT, Ezh2KO, and EedKO mice. Data are shown as mean ± SD.
(D and E) Sample FACS plots comparing BM LT-HSCs, ST-HSCs, and restricted lineage progenitors (RLP) of 9-day-old WT, Ezh2KO, and EedKO BM (D), and the
percentages are shown in the graph (E). Data are shown as mean ± SD.
(F–H) Graphs comparing Ezh1, Ezh2, and EedmRNA levels in 9-day-old WT BM LT-HSCs, ST-HSCs, RLPs, and MyePro cells. After normalized with expression
value of GAPDH, expression values of indicated genes in samples presented in each plot are compared to the smallest number within the group, which is set to 1.
Data are shown as mean ± SD.
See also Figure S2.
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Cell Stem Cell
PRC2 Regulates HSC Differentiation and MaintenanceEedKO HSCs Do Not Express c-Kit
The development of pancytopenia in EedKO neonates suggested
defects in HSCs. We examined EedKO hematopoietic stem/
progenitor cells (HSPCs) by flow cytometry. Strikingly, EedKO
BM lacked c-Kit-expressing cells within the lineage marker
negative-cell population (Lin). Thus, LinSca-1+Kit+ (LSK) cells
as well as the myeloid progenitor population (LinSca-1Kit+)
were nearly absent in EedKO BM (Figures 3A and 3B). However,
we observed a LinSca-1+Kit cell population, of which 33.1%
expressed the LT-HSC characteristic marker profile,
CD48CD150+ (Figure S2C). InWTBM, LinSca-1+Kit cell pop-
ulation was negligible and none of this subset was
CD48CD150+ (Figure S2B). These results suggest an alteration
of the LT-HSC surface phenotype in EedKO BM. Specifically,
EedKO BM LinSca-1+c-KitCD48CD150+ cells might be
authentic LT-HSCs that lack c-Kit expression. In support of
this, all LinSca-1+CD48CD150+ cells were c-Kit+ in WT
neonatal BM (Figure S2A). More importantly, EedKO BM
LinSca-1+CD48CD150+ cells expressed LT-HSC signature
genes (Ivanova et al., 2002) at levels comparable to WT
CD48CD150+ LSK cells, as assessed by gene set enrichment
analysis (GSEA) (Figure S2D). Furthermore, hierarchical
clustering analysis of microarray expression data clustered
EedKO BM LinSca-1+CD48CD150+ cells together with WT
LT-HSCs, forming a distinct group separated from WT short-
term HSCs (ST-HSCs) (Figure S2E). Together, these data
strongly support that LinSca-1+KitCD48CD150+ cells in
EedKO BM correspond to LT-HSCs in WT BM.
EedKO Neonatal BM LT-HSCs Are Defective in
Differentiation
The frequency of EedKO neonatal BM LT-HSCs (as percentage of
total BM cells) was significantly increased relative to WT
(0.715% ± 0.311% versus 0.015% ± 0.003%; p < 0.01; Fig-
ure 3C). However, after adjustment for the markedly reduced
number of total viable cells, no significant difference in cell
number of BM LT-HSCswas observed (11,371.4 ± 5,462 [EedKO]
versus 5,841.7 ± 206.0 [control]; p = 0.39; Figure 3C). Thus, a
block in differentiation and/or defects in cell proliferation/cell
death of EedKO HSPCs may account for the marked reduction
in mature lineage cells.
To explore these possibilities, we examined the frequencies of
LT-HSCs, ST-HSCs, and restricted lineage progenitor cells
(RLPs) (Kiel et al., 2005), which consisted of 7.74% ± 0.64%,
8.33% ± 0.78%, and 46.04% ± 3.67% of WT LSK cells, respec-
tively (Figures 3D and 3E). Percentages of LT-HSCs, ST-HSCs,
and RLPs in EedKO BM (percent of Lin-Sca-1+ cells) were
4.9-fold, 1.8-fold, and 0.08-fold of their WT correspondences,
respectively (Figures 3D and 3E). The ratio of LT-HSC versus
ST-HSC was markedly increased from 0.93:1 in WT to 2.46:1
in EedKO BM, and the RLP population was nearly absent. Taken
together, these data indicate that loss of Eed in HSPCs perturbs
the normal differentiation of LT-HSCs to ST-HSCs and, more
dramatically, the differentiation of ST-HSCs into restricted
lineage progenitor cells. Of note, the expression levels of Ezh2,
Ezh1, and Eed mRNAs were the highest in ST-HSCs relative to
LT-HSCs, RLPs, and myeloid progenitors (Figures 3F–3H),
suggesting a higher activity and dependency of PRC2 in ST-
HSCs than in other HSPCs.72 Cell Stem Cell 14, 68–80, January 2, 2014 ª2014 Elsevier Inc.EedMutant BM Cells Are Out-Competed by WT Cells in
Transplantation
The early lethality of EedKOmice precludes direct assessment for
the requirements of Eed in adult HSCs. Therefore, we crossed
EedFl/Fl mice with an Mx1Cre strain and the Rosa26R-enhanced
yellow fluorescent protein (EYFP) reporter mice (Ye et al.,
2003). The resulting mutant (EedFl/FlMx1CreRosa26R-EYFPFl/WT)
or control (EedFl/WTMx1CreRosa26R-EYFPFl/WT) mice were used
to conduct competitive BM transplantation assays (Figure 4A).
Following polyI:polyC (pIpC) administration, the percentage of
EYFP+ donor cells in mice receiving control cells increased
over time (Figure 4B). In contrast, the percentage of EYFP+
Eed mutant cells increased transiently after pIpC administration
and progressively decreased thereafter to a baseline of 20%
(Figure 4B). The residual EYFP+ mutant cells retained incom-
pletely excised Eed allele, in contrast to a complete excision of
floxed allele in the control EYFP+ cells (Figure S3B). Starting at
a ratio of 2:1 (CD45.2 donors versus CD45.1 competitors), it
increased to 3.8:1 in 5 months in the control cell recipients. In
contrast, this ratio was markedly reduced to 0.3:1 in the mutant
cell recipients (Figure 4C), indicating that Eed mutant BM cells
were out-competed by WT cells in the recipients.
Deletion of Eed Leads to Loss of Adult HSCs
To assess directly whether Eed is essential for adult HSC
maintenance, we compared relative ratios between Eed mutant
and WT HSCs (CD45.1) over time in a competitive repopulation
assay. Relative ratio was defined as the ratio of CD45.1 donor
versus CD45.2 competitor cells (BM, LSK cells, or LT-HSCs) of
a recipient mouse measured after pIpC administration relative
to the ratio of CD45.1 donor versus CD45.2 competitor blood
cells of the same mouse determined before pIpC injection. The
relative ratio of mutant LSK cells and LT-HSCs was reduced
by 35.2% and 38.2%, respectively, 1 week after pIpC adminis-
tration. These values for WT cells were 0.92 ± 0.06 and 0.92 ±
0.16, respectively. At 4 weeks post-pIpC injection, the relative
ratio of Eed mutant LT-HSCs fell to 0.07 ± 0.02 and donor-
derived LT-HSCs were nearly absent (Figure 4D). In contrast,
the relative ratio for control LSK cells and LT-HSCs remained
constant. These data demonstrate that Eed is required for main-
tenance of adult BM HSCs.
Loss of Eed Enhances Expression of Proliferation and
Differentiation Genes in LT-HSCs
To investigate the molecular basis underlying PRC2-regulated
HSC differentiation and maintenance, we compared gene
expression profiles of EedKO versus control LT-HSCs. Consis-
tent with a role for PRC2 in transcriptional repression, Eed loss
in HSCs was associated largely with gene derepression in both
neonatal and adult BMHSCs. Eed loss led to up- and downregu-
lation of 339 and 108 genes, respectively, in EedKO neonatal
LT-HSCs relative to controls at a 3-fold cutoff. At a 10-fold cutoff,
53 and 2 genes were up- or downregulated, respectively
(Figure 5B).
By integrated pathway analysis (IPA), we observed that the
differentially expressed genes (2-fold cutoff) are highly associ-
ated with hematopoietic development and function, cellular
growth and proliferation, cell death, and survival (Figure S4E).
GSEA analysis comparing neonatal EedKO and control BM
Figure 4. Loss of Eed in Adult HSCs Leads
to Their Exhaustion
(A) Scheme of competitive BM transplantation for
experiments conducted for (B) and (C).
(B) Changes in percentage of EYFP-positive cells
(of CD45.2+ donor cells) before and at different
time points after administration of pIpC. Data are
shown as mean ± SD.
(C) Graph represents ratios of donor- versus
competitor-derived cells (CD45.2 versus CD45.1)
in the blood at different time points after pIpC
administration. Data are shown as mean ± SD.
(D and E) Graph (D) showing the relative ratios of
CD45.1 versus CD45.2 BM cells, LSK cells, and
LT-HSCs at different time points after pIpC
administration. Relative ratio is defined as the
CD45.1 versus CD45.2 ratio of BM cells, LSK cells,
or LT-HSCs at certain time point post-pIpC
administration relative to the CD45.1 versus
CD45.2 ratio of blood cells of the corresponding
mouse before pIpC administration. Grey bars
represent EedWT/WTMx1CreRosa26R-EYFPFl/WT
cell (WT) recipients, and black bars represent
EedFl/FlMx1CreRosa26R-EYFPFl/WT cell (EedKO)
recipients. Data are shown as mean ± SD.
Representative FACS plots distinguishing donor-
(CD45.1) versus competitor (CD45.2)-derived BM
LT-HSCs are shown in (E).
See also Figure S3.
Cell Stem Cell
PRC2 Regulates HSC Differentiation and MaintenanceLT-HSCs revealed enrichment of genes involved in negative
regulation of cell-cycle progression (Figure S4C). The estab-
lished PRC2 target gene Ckdn2a (Jacobs et al., 1999), along
with other cell-cycle inhibitor genes, Cdkn1a and Cdkn2b,
were among the most highly upregulated genes in EedKO
HSCs (Figures 5A, 5C, 5D, and S5D). Inhibitors of HSPC differen-
tiation, Id2 and Sox7 (Costa et al., 2012; Gandillet et al., 2009; Ji
et al., 2008; Li et al., 2010), were also among the top upregulated
genes upon Eed loss (Figures 5A, 5C, and 5D). Additionally,
HoxC4, a homeobox gene that promotes self-renewal of HSCs
(Auvray et al., 2012; Daga et al., 2000), was also highly upregu-
lated in EedKO HSCs (Figures 5A, 5C, and 5D). Thus, loss of
Eed in HSCs leads to enhanced expression of a set of genes
involved in counteracting pathways, such as cell-cycle inhibitors
and proliferation enhancers, as well as genes that function to
block HSC differentiation. Importantly, loss of Eed enhanced
expression of these genes in both neonatal and adult LT-HSCs
(Figures 5C and 5D).
Deletion of Eed in BM LT-HSCs Activates Expression
of Proapoptotic Genes and Induces Cell Death
By GSEA analysis, we also observed enrichment of hypoxia
response genes, most are targets of Hif-1, in EedKO LT-HSCs
relative to controls (Figures S4A and S4B; data not shown).Cell Stem Cell 14, 68–Noxa, a direct target of Hif-1 and a BH3-
domain-only proapoptotic gene (Kim
et al., 2004), was the most highly upregu-
lated gene in EedKO LT-HSCs relative to
control LT-HSCs (Figures 5A, 5C, and
5D). In addition, p21 and Wig1, targets
of Arf/P53 that have been suggested toinduce cell death in Bmi-1-null HSCs (Park et al., 2003), were
also markedly upregulated in EedKO neonatal and adult BM
HSCs (Figures S5A and S5B). GSEA analysis comparing EedKO
and WT BM LT-HSCs confirmed the enrichment of proapoptotic
genes in EedKO HSCs (Figure S5C). Together, these data sug-
gest that EedKO HSCs are predisposed to apoptosis. To test
this, we performed annexin V and DAPI staining on HSPCs and
observed that 12.9% ± 1.9% of EedKO BM LT-HSCs were
apoptotic (annexin V+DAPI), a percentage that was 5.9-fold
greater than in WT LT-HSCs and 3.7-fold that of Ezh2/ LT-
HSCs, respectively (Figure 5E). More profound differences in
the rate of cell death were observed in restricted lineage progen-
itors, 31.6% ± 10.8% in EedKO BM versus 2.4% ± 0.9% in WT
BM, a striking 13.2-fold increase in EedKO cells relative to WT
cells (Figure 5E). Overall, these results demonstrate that loss of
Eed activates expression of proapoptotic genes and induces
cell death in the HSPC compartments, which may also partly
account for the decreased mature hematopoietic cells in
EedKO mice.
Derepressed Genes in EedKO HSCs Are Enriched for
H3K27me3 Targets
PRC2-mediated gene repression is heralded by the presence of
the H3K27me3 mark on, or surrounding, target genes. Because80, January 2, 2014 ª2014 Elsevier Inc. 73
(legend on next page)
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PRC2 Regulates HSC Differentiation and Maintenanceexpression of Cdkn1a, Cdkn2a/Cdkn2b, HoxC4, Id2, Sox7, and
Noxa was markedly elevated in Eed mutant HSCs, we asked
whether these genes are direct targets of PRC2 and marked by
H3K27me3. By chromatin immunoprecipitation (ChIP) analysis,
weobserved that, inWTLSKcells, the proximal promoter regions
of these genes were significantly enriched for H3K27me3, which
was largely depleted upon Eed loss (Figure 5F). These observa-
tions are consistent with the increased mRNA expression of
these genes inEedKOHSPCcells (Figures 5A, 5C, and 5D). These
data strongly suggest that these genes are directly targeted by
PRC2 and marked by H3K27me3 in wild-type HSPCs. Impor-
tantly, loss of Eed and H3K27me3 mark had minimal influence
on the levels of other histone marks, such as H3K9me3, at the
promoter regions of these genes (Figure 5G).
Compound Deletion of Cdkn2a Partially Rescues Eed
Mutant HSPCs
Deletion of Eed activated transcription of both Ink4a andArf from
the Cdkn2a locus (Figure S5D), an established Polycomb target
(Jacobs et al., 1999; Kotake et al., 2007). Deletion of Cdkn2a
has been reported to rescue the defects of some Polycomb
gene knockouts, such as Bmi1 and Ezh1 (Hidalgo et al., 2012;
Molofsky et al., 2005;Oguroet al., 2006). Therefore,weexamined
whetherCdkn2adeletion also rescues the hematopoietic defects
upon Eed loss. Compound deletion of Cdkn2a and Eed (DKO)
failed to rescue the neonatal lethality. Similar to the EedKO neo-
nates, DKO pups became pale within a couple of days after birth
(Figure 6A). White and red blood cell counts in DKO pups were
only 12.3% ± 8.2% and 14.2% ± 4.0% of WT littermates and
were not significantly different from EedKO neonates (p values =
0.44 and 0.75 for white blood cell [WBC] and red blood cell
[RBC], respectively; Figure 6B). The number of total BM cells in
7–9-day-old pups was 4.5-fold lower in EedKO than in WT
animalsandwasnot restoredupondeletionofCdkn2a (Figure3C;
data not shown). However, Cdkn2a deletion restored c-Kit
expression in HSPCs (Figure S6). Thus, LSK cells, which were
nearly absent in EedKO BM, consisted of 11.4% ± 3.4% of Lin
cells in DKO BM (Figures 3A and 6C), a frequency that was
2-fold greater than that of WT LSK cells (5.6% ± 1.7%). Cdkn2a
deletion also partially restored themyeloid progenitor population
to 13.2% ± 3.2% of Lin cells in DKO (Figure 6D), which was still
substantially lower than that of WTmyeloid progenitors (36.4% ±
4.5%). Therefore, the ratio of LSK versusmyeloid progenitor cells
in the DKO BM was 5.5-fold higher than that in the WT BM, sug-
gesting an accumulation of HSPCs in more immature stages,
likely caused by a block in cell differentiation.
Deletion of Cdkn2a in EedKO mice also enhanced HSPC
survival. Apoptotic LT- and ST-HSCs were reduced by 35.8%
and 33.9% in DKO BM relative to EedKO BM, respectively.
More strikingly, apoptotic restricted lineage progenitor cellsFigure 5. Loss of Eed in LT-HSCs Derepresses PRC2 Target Genes
(A and B) Heatmap of the top up- or downregulated genes (A) and overall gene
controls.
(C) Folds change of mRNA levels (mutant relative to WT) of indicated genes after
(D) Similar to (C) but comparing the expression of indicated genes after Eed loss
(E) Percentages of apoptotic BM LT-HSCs, ST-HSCs, and RLPs in neonatal WT
(F and G) ChIP-quantitative PCR analysis of H3K27me3 (F) and H3K9me3 (G) at t
mutant LSK cells from adult BMs. Data are shown as mean ± SD.
See also Figures S4 and S5.were decreased by 67.3% (Figures 6E and 6F). As a result, the
percentage of restricted lineage progenitor cells increased
4.5-fold in DKO BM relative to EedKO BM, though it remained
28.2% lower than in WT BM (Figure 6D).
The above results are in stark contrast to previous findings that
Cdkn2a deficiency rescued hematopoietic defects in Bmi1 and
Ezh1 knockout (KO) mice, enabling double KO bone marrow
cells to efficiently reconstitute of recipient hematopoietic system
in a competitive transplantation setting (Hidalgo et al., 2012;
Oguro et al., 2006). Deletion of Cdkn2a was unable to rescue
defects of EedKO BM in reconstituting recipient hematopoiesis.
EedKO BMcells were unable to form colony-forming units-spleen
or contribute to hematopoiesis in recipients (Figure S7). Thus,
deletion of Cdkn2a only partially enhanced the survival of EedKO
HSPCs without restoring HSC functions.
DISCUSSION
Here, we have investigated the requirement of PRC2 in hemato-
poiesis through conditional inactivation of its essential core sub-
unit, Eed. By this approach, we circumvented confounding
issues related to possible redundancy between Ezh1 and Ezh2,
as well as noncanonical functions of some PRC2 components.
We found that loss of Eed leads to multiple and profound defects
in hematopoiesis. Eed mutant HSCs fail to differentiate into
mature blood cells and are prone to cell death. PRC2 suppresses
the expression of numerous genes in HSCs, including differenti-
ation inhibitors, cell-cycle inhibitors, the self-renewal enhancers,
and the proapoptotic genes. Therefore, we infer that PRC2 coor-
dinates diverse pathways to ensure proper self-renewal and
differentiation of HSCs. Deletion ofCdkn2a enhances HSPC sur-
vival without relieving the differentiation blockage, further sug-
gesting that PRC2 governs multiple pathways in controlling
normal HSC functions. Whereas loss of Eed leads to derepres-
sion of similar genes in both neonatal and adult BM LT-HSCs,
different cellular phenotypes ensued. These contrasting out-
comes are most likely due to intrinsic differences in HSC prolifer-
ation and differentiation at different stages (Figure 7). The enrich-
ment of the H3K27me3mark at genes upregulated in Eedmutant
HSCs and depletion upon Eed loss demonstrate that they are
direct targets of PRC2. Therefore, relief of PRC2-mediated tran-
scriptional repression upon inactivation of Eed leads to the com-
plex and developmental-stage-specific hematopoietic defects.
Overlapping Function of Ezh1 and Ezh2 in HSCs
Ezh1 partially compensates for Ezh2 loss in embryonic and
skin stem cell (Ezhkova et al., 2009, 2011; Shen et al., 2008).
A similar mechanism is likely also at play in HSCs. We note
that loss of Ezh2 affects a smaller proportion of genes than
the loss of Eed (Table S1; Figure S4D). Of note, Ezh2 loss failsexpression changes upon Eed loss (B) in EedKO BM LT-HSCs compared to
loss of Ezh2 or Eed in neonatal BM LT-HSCs. Data are shown as mean ± SD.
in adult LT-HSCs. Data are shown as mean ± SD.
, Ezh2KO, or EedKO BM. Data are shown as mean ± SD.
he proximal promoter regions of indicated genes in FACS-sorted WT and Eed
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Figure 6. Deletion of Cdkn2a Partially
Rescues Eed Loss in Hematopoiesis
(A) Representative photo of 8-day-old WT, EedKO,
and DKO pups.
(B) WBC and RBC counts of 9-day-old control and
mutant pups. Data are shown as mean ± SD.
(C and D) Deletion ofCdkn2a partially restores LSK
and MyePro populations (C) as well as more
primitive progenitors (D) in DKO. Data are shown
as mean ± SD.
(E and F) Deletion of Cdkn2a enhances HSPCs
survival. Different HSPC populations are stained
with annexin V and DAPI (E), and the percentages
of early apoptotic cells (annexin V+DAPI) are
shown in graph (F). Data are shown as mean ± SD.
See also Figures S6 and S7.
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genes and thus preserves largely normal differentiation and
functions of HSPCs. Moreover, expression of Noxa, Wig1,
and Perp is derepressed to a much lesser extent in Ezh2KO
LT-HSCs compared to EedKO LT-HSCs. Surprisingly, Ezh2
loss fails to derepress expression of Cdkn2a in LT-HSCs (Fig-
ure 5C), which is highly upregulated in Ezh1 mutant HSCs
(Hidalgo et al., 2012). Consistent with these gene-expression
changes, apoptosis is also only slightly increased in Ezh2KO
relative to WT LT-HSCs (Figures 5C and 5E). Such differences
may account for a smaller reduction in the number of BM
HSCs in Ezh2KO relative to EedKO (Figure 3C). Together, these
results suggest that Ezh1- and Ezh2-containing PRC2 com-
plexes have selective targets and that Ezh1 compensates for
Ezh2 loss at some, but not all, PRC2 targets. In adult HSCs,
Ezh2 loss exerts even fewer effects on HSCs, in consistent
with elevated Ezh1 level and decreased Ezh2 expression at
this stage (Figures 1G and 1H). Of note, Ezh1 mRNA does76 Cell Stem Cell 14, 68–80, January 2, 2014 ª2014 Elsevier Inc.not increase upon the loss of Ezh2 in
BM HSCs (data not shown).
Ezh2 was reported to be essential for
FL, but not adult BM, HSCs on the basis
of conditional deletion mediated by
Tie2Cre (Mochizuki-Kashio et al., 2011).
In our study, VavCre-mediated Ezh2 exci-
sion failed to reproduce a similar pheno-
type in FL HSCs, most likely due to the
application of different Cre lines.Whereas
VavCre mediates gene deletion specif-
ically in hematopoietic cells, Tie2Cre also
induces excision in endothelial cells
(Kisanuki et al., 2001). Therefore, the
described FL HSC defects may not be
due to a cell-autonomous effect.
Roles of Canonical versus
Noncanonical PRC2 in
Hematopoiesis
Canonical PRC2 consists of three core
subunits, Eed, Suz12, and Ezh1/Ezh2,
and methylates H3K27. H3K27me3 is
considered to be a mark for repressedor poised genes, depending on the coexistence of activation
marks (Bernstein et al., 2006). More recently, core subunits
of PRC2 have been found to bind to regions where
H3K27me3 is absent and associate with active genes (Lee
et al., 2011; Mousavi et al., 2012; Xu et al., 2012), suggesting
that they may have noncanonical functions that are
independent of PRC2 histone substrate. Eed associates almost
exclusively with methylated H3K27 (J.X. and S.H.O., unpub-
lished data). Hence, Eed deletion likely abolishes all canonical
PRC2 function without compromising noncanonical PRC2
activities. Close comparisons between Ezh1, Ezh2, and Eed
knockouts and Ezh1/Ezh2 double knockout mice will be very
informative in distinguishing canonical versus noncanonical
PRC2 functions and their roles in differentiation and develop-
ment. For example, the ratio of up- versus downregulated
genes, comparing Ezh1/ to WT HSCs, is 1.56:1 (Hidalgo
et al., 2012). This value is 3.13:1 in EedKO HSCs relative to
WT HSCs (Figure 5B; 3-fold cutoff), indicating that more genes
Figure 7. PRC2 Regulates HSC Differentia-
tion and Survival
(A) PRC2 suppresses target genes in WT HSCs.
Purple ovals represent methyl groups.
(B) Some PRC2 target genes are selectively
derepressed in EedKO BM HSCs.
(C and D)WT (C) and EedKO (D) neonatal BMHSCs
self-renew and differentiate in a BM niche. Eed
loss leads to a differentiation block ([D], red bars)
and apoptosis ([D], cells with black dots) of some
HSCs without significantly affecting HSC number.
(E and F) Similar to (C)–(D) but showing WT (E) and
Eed mutant (F) adult BM HSCs. Apoptosis
becomes the dominant effect of Eed loss in adults,
resulting in HSC failure.
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deletion of Ezh1 resulted in downregulation of many genes
crucial for HSC functions, such as Gata3, Runx1, Meis1,
Pten, and Pbx1, which may in part be responsible for the
HSC defects (Hidalgo et al., 2012). Strikingly, none of these
genes is affected in EedKO HSCs. Therefore, Eed likely acts
through the canonical PRC2 complex regulating genes to
ensure normal HSC maintenance and differentiation. In
contrast, Ezh1 may participate in control through both canon-
ical and noncanonical PRC2 functions.
Complex Consequences of Eed Loss in HSCs
Gene expression is controlled by the availability of appropriate
transcription factors plus the accessibility of their correspond-
ing binding sites on the genome (Reik, 2007). In HSCs, Eed
loss enhances expression of genes of various pathways,
including differentiation inhibitors, apoptotic genes, prolifera-
tion enhancers, and cell-cycle inhibitors. These genes exertCell Stem Cell 14, 68–conflicting effects in cellular phenotypes
(Figures 5A, 5C, 5D, and S4E) and may
account for the profound and complex
consequences of Eed loss during hema-
topoiesis. In addition, intrinsic differ-
ences in neonatal and adult BM HSCs
integrate with the effects of Eed loss, re-
sulting in developmental-stage-specific
phenotypes in HSCs. Neonatal BM
HSCs actively proliferate for 2 to 3 weeks
after birth and become quiescent there-
after (Bowie et al., 2006). EedKO neonatal
HSCs are likely impaired in differentia-
tion, in part due to the derepression of
differentiation inhibitors, thereby trap-
ping them within the HSC pool. Mean-
while, elevated HoxC4 expression upon
Eed loss may further enhance HSC
self-renewal. On the other hand, Eed
loss also promotes quiescence through
derepression of CDK inhibitor expres-
sion. Moreover, upregulation of Noxa
and other cell-death genes favors
apoptosis of HSCs. In essence, Eed
mutant HSCs face conflicting signals toexpand the HSC pool, block proliferation, and trigger cell
death. The net outcome of Eed inactivation may depend on
the relative strength of these interacting conflicting signals.
Furthermore, the deleterious effects of Eed loss for HSCs
also depend on cellular context. Specifically, neonatal BM
HSCs undergo a high rate of self-renewal divisions to achieve
a steady-state adult HSC pool. Concomitantly, more neonatal
HSCs are called into differentiation than in the adults in order
to supply the growing individual with sufficient intermediate
progenitors. Hence, inhibition of HSC differentiation in EedKO
neonates, together with potentially enhanced proliferation, con-
tributes sufficient cells to the HSC pool to compensate for
those lost by increased apoptosis and cell-cycle inhibition (Fig-
ures 7C and 7D). In contrast, few adult LT-HSCs are in cell
cycle or initiating differentiation under normal circumstances
(Wilson et al., 2008). Therefore, in this setting, apoptosis
becomes the dominant effect of Eed inactivation in adult LT-
HSCs (Figures 7E and 7F).80, January 2, 2014 ª2014 Elsevier Inc. 77
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EedKO HSPCs
Cdkn2a deletion partially rescued Eed-deficient HSPCs from cell
death, most dramatically within the restricted lineage progenitor
population. Reduced cell death was not as significant inCdkn2a/
Eed DKO LT-HSCs (Figure 6F). Derepression of Cdkn2a expres-
sion in HSPCs upon loss of Polycomb proteins has been sug-
gested to induce cell death though downstream targets of p53,
including P21 andWig1 (Park et al., 2003). In EedKO BM, Cdkn2a
andWig1were upregulated the highest in restricted lineage pro-
genitor cells relative to LT- and ST-HSCs (Figure S5A). In
contrast, Noxa was upregulated the highest in LT-HSCs (Fig-
ure S5A).Noxa is a direct target of both PRC2 andHif-1, the latter
of which is expressed at its highest level in LT-HSCs among
other HSPCs (Takubo et al., 2010). Therefore, inactivation of
Cdkn2a is unable to curtail Noxa expression in DKO LT-HSCs
and consequently only slightly decreases apoptosis of DKO
LT-HSCs compared to EedKO HSCs. Moreover, knockout of
Cdkn2a fails to significantly downregulate inhibitors of HSPC dif-
ferentiation (Figure S5B) and to rescue the differentiation block in
DKO HSPCs. Together, our data indicate that PRC2 suppresses
genes of diverse pathways ensuring normal HSC functions and
inactivation of a single target gene, such as Cdkn2a, is insuffi-
cient to rescue the defective EedKO HSCs.
EedD/WT BM HSCs Exhibit a Growth Advantage
in Competitive Transplantation
Previous studies have shown that BM cells heterozygous for an
ENU-induced, loss-of-function mutation of Suz12 exhibit
enhanced competitive reconstitution capacity (Majewski et al.,
2008), suggesting a suppressive role of PRC2 in HSC activity.
Consistent with this finding, we observed that adult BM HSCs
heterozygous for Eed (EedFl/WTMx1CreRosa26R-EYFPFl/WT,
referred to as EedD/WT HSCs) out-competed WT HSCs in a
competitive transplantation setting (Figures 4C and S3A). How-
ever, a complete loss of Eed gene leads to HSC exhaustion in
the adult BM (Figures 4C and 4D). On the other hand, overex-
pression of Ezh2 has been reported to augment HSC prolifera-
tion and forestall its exhaustion in serial transplantation assays
(Herrera-Merchan et al., 2012; Kamminga et al., 2006). Taken
together, these data suggest that proper HSC function necessi-
tates fine-tuned control of PRC2.
Despite a selective growth advantage of EedD/WT HSCs, no
leukemia was observed in the recipients in a 1-year period after
BM transplantation and pIpC administration (data not shown).
Similarly, no leukemia was observed in mice with heterozygous
loss of Ezh2 or Eed by VavCre for at least 18 months (data not
shown), although inactivation of both alleles of Ezh2 by Mx1Cre
leads to T-cell acute lymphoblastic leukemia in mice (Simon
et al., 2012). Thus, inactivation of a single copy of Eed enhances
cell proliferation but is insufficient to trigger leukemogenesis.
Additional mutations are likely needed for generation of
hematopoietic malignancies in individuals with heterozygous
mutation of PRC2 (Makishima et al., 2010; Ntziachristos et al.,
2012).
Conclusions
Loss of Eed in BM HSCs produces devastating and complex
consequences by triggering counteracting and conflicting sig-78 Cell Stem Cell 14, 68–80, January 2, 2014 ª2014 Elsevier Inc.nals that control cell-cycle inhibition, self-renewal, differentia-
tion, and apoptosis. The effects of Eed loss in the hematopoietic
system far exceed the loss of Ezh2 or Ezh1 alone. Current efforts
of targeting PRC2 for therapy have centered primarily on inhibi-
tion of Ezh2, as its overexpression characterizes many cancers,
both hematopoietic and nonhematopoietic in origin (Sauvageau
and Sauvageau, 2010; Simon and Lange, 2008). In those circum-
stances, in which oncogenesis strictly depends on Ezh2, this
strategy is predicted to be successful (Wilson et al., 2010). In
other settings, such as in some leukemias, inactivation of all ca-
nonical PRC2 function may be required (Neff et al., 2012; Shi
et al., 2013). Our study reveals the complex consequences of
PRC2 loss for hematopoiesis and demonstrates its essential
roles in HSC differentiation, self-renewal, and survival. Further
work is needed to elucidate regulation of Ezh1 and Ezh2 expres-
sion during development, as well as how Ezh1- and Ezh2-con-
taining PRC2 complexes attain their target specificity.
EXPERIMENTAL PROCEDURES
Generation of Eed Conditional Allele and Mice
Genomic sequences spanning introns 1 and 2, introns 2–6, and introns 6–8
were generated by PCR and subcloned into the modified pFlexible vector at
the sites of ClaI/AscI, Pac1, and NotI, respectively. Positive clones were
validated by Southern blot analysis. The neomycin cassette was removed by
transient expression of Flp recombinase and validated by PCR. Two karyotyp-
ically normal ESC clones were injected into blastocysts to generate chimeras.
The Institutional Animal Ethics Committee of Boston Children’s Hospital
approved all animal experiments.
Flow Cytometry
Cells were first incubated with Fc-Block and then with biotin-conjugated line-
age marker antibodies (CD3e [145-2C11], CD4 [GK1.5], CD5 [53-7.3], CD8a
[53-6.7], CD11b [M1/70], B220 [RA3-6B2], Gr-1 [RB6-8C5], and Ter119
[TER119]) and followed by Percp-Cy5.5-conjugated streptavidin, phycoery-
thrin (PE)-Cy7-conjugated Sca-1 (D7), allophycocyanin (APC)-Cy7-conjugated
c-Kit (2B8), PE-conjugated CD48 (HM48-1), and APC-conjugated CD150
(TC15-12F.2) antibodies. After washing, labeled cells were run on LSR II/
LSR Fortessa for analysis or on FACSAria II for cell sorting. Fluorescence-
activated cell sorting (FACS) data were analyzed with Flowjo software (Tree
Star).
Global Gene Expression Profiling
Total RNA was isolated using the RNeasy Micro Plus Kit (QIAGEN), reverse
transcribed, amplified with the WT-Ovation Pico RNA Amplification System
V2 (NuGEN), labeled (NuGEN; Encore Biotin Module), and hybridized to
Affymetrix mouse 430A 2.0 arrays. Data were analyzed with GenePattern,
GSEA, and IPA.
ChIP-Quantitative PCR
ChIP was performed as described with modifications (Xu et al., 2010). Briefly,
2.5–53 105 of FACS-sorted LSK cells were crosslinkedwith 1% formaldehyde
(Calbiochem) for 5 min at room temperature. Chromatin was sonicated in
radioimmunoprecipitation assay buffer (RIPA) with 0.3 M NaCl to 500 bp.
Dynabeads Protein A (Invitrogen) was used for collection of chromatin. One
to two micrograms of antibodies per immunoprecipitation were incubated
with beads for 35 hr before incubating with sonicated chromatin for over-
night. ChIP DNA was purified and quantified by real-time PCR using the iQ
SYBR Green Supermix (Bio-Rad). Anti-H3K27me3 (07-449, Millipore) and
anti-H3K9me3 (17-625, Millipore) antibodies were used for the analyses.
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